Biotechnology

Friday Jul 28, 2023 - 12:27 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets

BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company is developing a pipeline of unique nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments with large, growing markets, including dermatological conditions such as psoriasis. “BiondVax is initially targeting IL-17 [the human immune system cytokine,…

Thursday Jul 27, 2023 - 11:12 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its abstract was selected for in-person poster presentation at the 2023 SNO/ASCO CNS Cancer Conference taking place in San Francisco from Aug. 10-12, 2023. Sandra Silberman, MD, PhD, chief medical officer of CNS…

Thursday Jul 27, 2023 - 10:38 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q2 2023 Results Call, Webcast

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced that it will hold a conference call to discuss its results for the second quarter ended June 30, 2023. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno and CFO Richard Brounstein will host the call at 4:30…

Wednesday Jul 26, 2023 - 12:42 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Physician, Researcher to Board of Directors

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has announced a new member of its board of directors: Michael R. Jaff, DO. This appointment brings the number of board members to eight. A renowned vascular physician and researcher, Jaff has an impressive background in the clinical and industry…

Tuesday Jul 25, 2023 - 3:02 pm

InvestorNewsBreaks – HippoFi Inc. (ORHB) Announces Launch of PURmarrow 360, Strategic Partnership for Near-Term Commercialization of New Technology

HippoFi (OTC: ORHB) is a leading health care technology company and authority in spinal biologics, focused on the development and distribution of innovative biotech products. The company today announced that, over the last six months, while under a confidential letter of intent (“LOI”) in a strategic partnership, it has designed and formulated a strategic launch of the PURmarrow 360 bone marrow aspirate (“BMA”) device throughout…

Tuesday Jul 25, 2023 - 2:43 pm

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW), Partners Launch Proven Breakthrough Hair-Booster System in India

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, in partnership with its regional distributors, has launched Cosmofix MinoxiBoost in India. JUPW’s distributors are Sanpellegrino Cosmetics Pvt Ltd and Cosmofix Technovation Pvt Ltd, which have exclusive distribution rights to the company’s patented hair-growth technology in 31 countries in Asia and the Middle East including India, the Philippines, Malaysia, Kuwait, Morocco and Saudi…

Monday Jul 24, 2023 - 3:03 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) CDMO Services Designed to Meet Needs of Pharmaceutical, Biotechnology Companies of All Sizes

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company recently showcased its boutique end-to-end contract development and manufacturing organization (“CDMO”) services and expertise at a leading conference for International Life Science and HealthTech industries, the Biomed Conference, in Tel Aviv. “These CDMO services will allow BiondVax to…

Friday Jul 21, 2023 - 11:10 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Water Tower Research Fireside Chat Series

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that Jerry Griffin, VP of Sales and Marketing for InMed’s subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market, will be participating in a fireside chat with Water Tower Research on July…

Thursday Jul 20, 2023 - 11:03 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Board Appointments of GBB Drink Lab Founder and President and Beverage Industry Veteran

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced the appointment of John Gulyas to its board of directors and Rich Pascucci to its advisory board. Both Gulyas and Pascucci are formerly from GBB Drink Lab, creator of Safety Shot, the world’s first rapid blood alcohol detoxification drink recently acquired by Jupiter Wellness. “We are very pleased to have more…

Thursday Jul 20, 2023 - 10:30 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market. Among the highlights, the company reported a 123% quarter-over-quarter increase in revenues. “We are very encouraged to see another…

Wednesday Jul 19, 2023 - 11:24 am

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sector

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it was granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office (“USPTO”). According to the update, U.S. patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine…

Wednesday Jul 19, 2023 - 10:39 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its entry into definitive agreements with health care-focused institutional investors. The agreements are for the sale and issuance of 7,425,744 shares of the company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01…

Tuesday Jul 18, 2023 - 11:01 am

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Presenting 6 Posters on Its Lead Therapeutic Candidate at AAIC 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced that it is presenting six in-person posters highlighting data from its phase 1 clinical trials investigating the company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference (“AAIC”). The event is taking place July 16-20, 2023, in Amsterdam, Netherlands. “We are honored to have six posters accepted for presentation at AAIC 2023, a…

Tuesday Jul 18, 2023 - 10:11 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting that an arbitration panel has found that Syneos Health (NASDAQ: SYNH) failed to use commercially reasonable efforts in conducting its trial for FSD 201. According to the announcement, Syneos Health filed…

Monday Jul 17, 2023 - 2:15 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, anti-PD1 resistant, human NSCLC metastases in humanized mouse models, presenting…

Tuesday Jul 11, 2023 - 11:40 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Expands C-Suite to Welcome Key GBB Drink Lab Execs

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced that, along with the asset purchase agreement for the company’s purchased and provisional patents, two GBB Drink Lab executives will join Jupiter Wellness’ C-suite. Josh Wagner, the former U.S. director of sales for Anheuser Busch, where he led a $12 billion business with a 72 person sales team to their best…

Monday Jul 10, 2023 - 11:32 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Moves to Acquire ‘Safety Shot’ – the World’s First Rapid Blood Alcohol Detox Drink

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced it has executed an asset purchase agreement with GBB Drink Lab Inc. Under the agreement, all operating assets related to GBB Drink Lab, including the revolutionary Safety Shot beverage, will belong to Jupiter Wellness. Safety Shot, which is protected by a number of issued and pending patents covering composition of matter…

Wednesday Jul 05, 2023 - 1:25 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in July’s Virtual Investor Summer Spotlight Series

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in the Virtual Investor Summer Spotlight Series. Company CEO John Climaco and chief medical officer Sandra L. Silberman will both be participating on a live webcast scheduled for July 11, 2023, at 12 p.m. ET. The…

Monday Jul 03, 2023 - 11:32 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well Positioned to Move next NanoAb Candidates into Clinical Application

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). “The license agreement is part of a broad-based collaboration with the Max Planck Society and the University Medical Center Göttingen (‘UMG’). The NanoAbs…

Friday Jun 30, 2023 - 1:39 pm

InvestorNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Closes on Public Offering Totaling About $8.5M

Panbela Therapeutics (NASDAQ: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, has closed on its previously announced public offering. The offering consisted of 2,270,000 shares of its common stock or prefunded warrants in lieu thereof as well as two classes of warrants to purchase up to 4,540,000 shares of common stock (public warrants). The offerings were…

Wednesday Jun 28, 2023 - 3:27 pm

InvestorNewsBreaks – XSurgical to Host July 11 Webinar

XSurgical Inc., an artificial intelligence surgical robotics company, has announced that it will host a Q&A webinar at 11 a.m. Pacific Time on July 11, 2023. Led by co-founder and CEO Dr. Gianluca De Novi and Chairman of the Board Michele Marzola, the focus of the online event will be to discuss XSurgical as a business, as well as the company’s equity crowdfunding raise on…

Wednesday Jun 28, 2023 - 10:38 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Sets Record Date for SRM Entertainment Spin-Off, Share Distribution

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has announced the record date for the spin-off and distribution of common stock shares, par value $0.0001 per share, of SRM Entertainment Inc. SRM is a majority-owned subsidiary of Jupiter. According to the announcement, the record date is slated for July 7, 2023. On that date, company stockholders and holders of…

Monday Jun 26, 2023 - 3:34 pm

InvestorNewsBreaks – MoonLake Immunotherapeutics’ (NASDAQ: MLTX) Shares See Significant Increase Based on Success of IL-17 Nanobody Phase 2 Trial

MoonLake (NASDAQ: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, has announced positive top-line results from its global phase 2 MIRA trial. The trial (“M1095-HS-201”) evaluated the efficacy and safety of the Nanobody(R) Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (“HS”). MoonLake’s shares closed nearly $20.00 up on the day to $45.95 following the recent news. “As part of our…

Friday Jun 23, 2023 - 1:42 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. Silo intends to leverage its existing partnerships with academic research institutions to help move the novel treatment for chronic pain sufferers through the Food and Drug…

Friday Jun 23, 2023 - 12:06 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, was featured in a video published by InvestmentPitch Media. FSD Pharma recently entered into a non-binding letter of intent with 1319741 B.C. Ltd., an unlisted reporting issuer, which will be renamed Celly Nutrition Inc. FSD…

Thursday Jun 22, 2023 - 11:37 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) 755-201-EB Trial Demonstrates Clinically Important Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced safety and efficacy results from its phase 2 clinical trial. The purpose of the trial, called “755-201-EB,” was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of…

Thursday Jun 22, 2023 - 10:35 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $40M Public Offering

Clene (NASDAQ: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, recently announced the pricing of an underwritten public offering. The offering consists of 50,000,000 shares of its common stock and two tranches of warrants (each warrant to purchase one share of common stock) at a combined public…

Wednesday Jun 21, 2023 - 2:13 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a…

Wednesday Jun 21, 2023 - 10:17 am

InvestorNewsBreaks – Bone Biologics Corporation (NASDAQ: BBLG) Announces $5M Underwritten Public Offering

Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, recently announced the pricing of an underwritten public offering of common stock. The company is selling 2,538,071 shares of its common stock in the offering, each at a price to the public of $1.97, for aggregate gross proceeds of approximately $5.0 million. In addition, Bone Biologics has granted the underwriters an over-allotment…

Tuesday Jun 20, 2023 - 11:56 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Grant Exclusive Rights to Recreational Alcohol Misuse Technology

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced its entry into a non-binding letter of intent. The agreement, dated June 19, 2023, is with 1319741 B.C. Ltd., which will be renamed “Celly Nutrition Inc.” (“Celly Nu”), an unlisted reporting…

Friday Jun 16, 2023 - 2:26 pm

InvestorNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC”) who have experienced disease progression after previous treatments. “REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat…

Monday Jun 12, 2023 - 1:42 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Big Pharma Competencies to Bring Innovative Therapies to Market Quicker, at Lower Cost

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently published Q1 2023 financial results and provided a business update. “The Q1 2023 results were in line with analysts’ expectations. R&D expenses increased about $800,000 from Q1 2022, which BiondVax attributed to the initiation and ramp-up of R&D activities for…

Thursday Jun 08, 2023 - 1:16 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Wealth of Expertise to Its Board with Appointments of Ken Nelson and Mark Strome

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced the appointment of Ken Nelson and Mark Strome to its board of directors, effective as of June 5, 2023. Nelson is a 20-year digital health, medical device and remote patient monitoring executive and innovator. Strome brings experience combining over…

Wednesday Jun 07, 2023 - 2:59 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the NRPL2 tumor suppressor gene. “The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (‘NSCLC’) humanized mouse models. Genprex’s ONCOPREX(R) Nanoparticle Delivery System is…

Tuesday Jun 06, 2023 - 12:30 pm

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives Notice of Allowance for Patent on IGC-501

IGC Pharma (NYSE American: IGC) today announced its receipt of a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (“IGC-501”). The formulation additionally received an intent to grant from the European Patent Office. With these and a previous award, the formulation for treating seizures is protected in the U.S., Canada…

Tuesday Jun 06, 2023 - 11:08 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Successful SPAC Transaction

Jupiter Wellness (NASDAQ: JUPW) today announced the successful de-SPACing and commencement of trading of its sponsored special purpose acquisition company (“SPAC”), now trading on Nasdaq under the ticker symbol CJET. According to the update, the transition highlights Jupiter’s commitment to innovative growth strategies and broadening its investment portfolio. “Jupiter is proud to have been a part of this successful SPAC transaction, reflecting our confidence in…

Thursday Jun 01, 2023 - 10:37 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Sponsored Research Presented at Canadian Neuroscience Meeting

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids, today announced that results from a neurodegenerative disease study were presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates that…

Thursday Jun 01, 2023 - 10:14 am

InvestorNewsBreaks – Biocept Inc. (NASDAQ: BIOC) Releases Pricing on Public Offering

Biocept (NASDAQ: BIOC), a leading provider of molecular diagnostic assays, products and services, is reporting the pricing of its underwritten public offering. The offering is comprised of 1,176,470 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock. The shares will be offered at a combined price of $4.25 per…

Thursday May 25, 2023 - 1:04 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Board Appointment of Dr. Eric Hoskins

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the appointment of Dr. Eric Hoskins to its board of directors. A medical doctor, Dr. Hoskins is specialized in public health and presently a partner at Maverix Private…

Thursday May 25, 2023 - 12:36 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Granted Key Patent for Use in Innovative System Designed to Help Evaluate Cardiac Symptoms

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has been granted a patent for the automated cardiac detection technology used in its AIMIGo(TM) System. The company received a notice of allowance from the U.S. Patent and Trademark Office informing the company of the key patent, which relates to…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions